Table 1 Study characteristics.

Study	Location and Year	No. centers involved	Study design	LAMS delivery system	Total patients (no.)	Gender, Male %	Age (median; range/mean ± SD)	CBD diameter (median; range/mean ± SD)	Technical success %	Clinical success %	Study	Location and Year
Kunda	Denmark, 2016	7	Retrospective study	Cold & Hot Axios, Boston Scientific Corp.	57	54.4	73;49–93	17.9; 8–35	98.2	94.7	Kunda	Denmark, 2016
Tsuchiya	Japan and Hong Kong, 2017	5	Prospective Cohort study	Hot Axios, Boston Scientific Corp.	19	63.2	70.6 ± 13.9	17.3 ± 5.5	100.0	94.7	Tsuchiya	Japan and Hong Kong, 2017
Jacques	France, 2018	10	Retrospective study	Hot Axios, Boston Scientific Corp.	52	48.1	78;61–92	Not Reported	88.5	98.1	Jacques	France, 2018
El Chafic	USA, 2019	6	Retrospective study	Hot Axios, Boston Scientific Corp.	67	55.2	68.8 ± 11.8	17.6 ± 3.6	95.5	100.0	El Chafic	USA, 2019
Anderloni	Italy, 2019	1	Retrospective study	Hot Axios, Boston Scientific Corp.	46	52.2	73.1 ± 12.6	17.26 ± 3.34	93.5	97.7	Anderloni	Italy, 2019
Yung-Lun Chin	New Zealand, 2020	1	Retrospective study	Hot Axios, Boston Scientific Corp.	60	56.7	76;52–90	17 ± 10	100.0	85.0	Yung-Lun Chin	New Zealand, 2020
Jacques	France, 2020	7	Retrospective study	Hot Axios, Boston Scientific Corp.	70	54.3	75 ± 11	17.7 ± 5	98.6	98.6	Jacques	France, 2020
Garcia-Sumalla	Spain, 2021	3	Retrospective study	Hot Axios, Boston Scientific Corp.	22	24.4	75.3 ± 12.1	17.5; 9–27	95.5	77.3	Garcia-Sumalla	Spain, 2021
Bun Teoh	Korea, China, Thailand, Hong Kong, 2021	5	Prospective cohort study	S-LAMS (Niti-S Spaux, Taewoong Medical, Gyeonggi-do, Korea)	26	46.2	64.1 ± 13.2	Not reported	88.5	88.5	Bun Teoh	Korea, China, Thailand, Hong Kong, 2021
Fugazza	Italy, 2022	23	Retrospective study	Hot Axios, Boston Scientific Corp. and Nagi Stent	256	55.1	73.9 ± 12.6	17.3 ± 3.9	93.4	96.2	Fugazza	Italy, 2022
Ginestet	France, 2022	1	Retrospective study	Hot Axios, Boston Scientific Corp.	50	60.0	76.5 ± 0	Not reported	98.0	90.0	Ginestet	France, 2022